You are using an outdated browser. Please upgrade your browser to improve your experience and security.

National Comprehensive Cancer Network® (NCCN®) recommendations

Liposomal daunorubicin and cytarabine (VYXEOS) is the ONLY treatment recommended in the NCCN Clinical Guidelines in Oncology (NCCN Guidelines®) for induction in patients ≥60 years of age with therapy-related AML or antecedent MDS/CMML or AML-MRC (Category 1)1

Liposomal daunorubicin and cytarabine (VYXEOS) is recommended for the following patients1:

≥60 years Treatment
Category 1
recommendation
Induction
therapy
Therapy-related AML or antecedent MDS/CMML or AML-MRC (AML-5)
Category 2A
recommendation
Reinduction Patients with residual disease (preferred only if given in induction) (AML-7)
Consolidation Postremission therapy in patients with complete response (preferred only if given in induction) (AML-8)
<60 years Treatment
Category 2B
recommendation
Induction
therapy
Therapy-related AML other than CBF/APL or antecedent MDS/CMML or cytogenetic changes consistent with MDS (AML-MRC) (AML-1)
Category 2A
recommendation
Reinduction Patients with significant residual disease without a hypocellular marrow (preferred only if given in induction; bone marrow aspirate and biopsy 14-21 days after start of therapy) (AML-2)
Consolidation Postremission therapy in treatment-related disease other than CBF and/or unfavorable cytogenetics and/or molecular abnormalities (preferred only if given in induction) (AML-4)
≥60 years
Category 1 recommendation
Induction therapy: Therapy-related AML or antecedent MDS/CMML or AML-MRC (AML-5)
Category 2A recommendation

Reinduction: Patients with residual disease (preferred only if given in induction) (AML-7)

Consolidation: Postremission therapy in patients with complete response (preferred only if given in induction) (AML-8)
<60 years
Category 2B recommendation
Induction therapy: Therapy-related AML other than CBF/APL or antecedent MDS/CMML or cytogenetic changes consistent with MDS (AML-MRC) (AML-1)
Category 2A recommendation

Reinduction: Patients with significant residual disease without a hypocellular bone marrow (preferred only if given in induction; bone marrow aspirate and biopsy 14-21 days after start of therapy) (AML-2)

Consolidation: Postremission therapy in treatment-related disease other than CBF and/or unfavorable cytogenetics and/or molecular abnormalities (preferred only if given in induction) (AML-4)

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.